Sedana Medical AB (SEDANA) AI Stock Analysis

• Market Cap: €1.22B
• Dividend Yield: N/A
• Average Volume (3M): 247.68K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.15
• Revenue Growth: 16.27%
• EPS Growth: -22.61%
• Country: SE
• Employees: 113
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.13
• Shares Outstanding: 99,336,960
• 10 Day Avg. Volume: 186,290
• 30 Day Avg. Volume: 247,675
• PEG Ratio: 2.17
• Price to Book (P/B): 1.98
• Price to Sales (P/S): 10.60
• P/FCF Ratio: -10.15
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €14.01
• Price Target Upside: 14.43% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: kr14.00 ▲(14.38% Upside)

Sedana Medical AB's overall stock score is primarily impacted by its financial performance, which shows revenue growth but significant profitability and cash flow challenges. Technical analysis indicates a bearish trend, and valuation metrics are weak due to negative earnings.

Sedana Medical AB Business Overview & Revenue Model

Company Description

Sedana Medical AB (publ), a medical technology company, develops, markets, and sells medical devices in Sweden and internationally. The company offers Sedaconda ACD-L and Sedaconda ACD-, which are disposable medical devices that enables the administration of volatile anesthetics; Sedaconda Syringe, a 50/60ml syringe; Sedaconda ACD starter kit; FlurAbsorb and FlurAbsorb-S, which are active carbon filters to capture waste anaesthetic gases from the exhaust of the ventilator; FlurAbsorb accessory kit comprising accessories to connect the exhaust of the ventilator and the gas monitor to the FlurAbsorb/FlurAbsorb-S; and FlurAbsorb mount to hold the filter during scavenging of anesthetic gas. It also provides AMG-06 Gas Monitor for continuous non-invasive sidestream monitoring of CO2 and anaesthetics concentration in inspired and expired gases; Sedaconda Filling Adapter, a single-use device for safe and easy extraction of isoflurane from a Sedaconda bottle to a Sedaconda Syringe; and various accessories comprising DRYLINE II Water Traps, WaterLock 2 water trap, Nafion Dryer Tubing, and Respiratory Gas Monitoring Line. Sedana Medical AB (publ) was founded in 1999 and is headquartered in Danderyd, Sweden.

How the Company Makes Money

Sedana Medical generates revenue through the sale of its medical devices, primarily the AnaConDa system, and related consumables. The company earns money from direct sales to hospitals and healthcare facilities, as well as through partnerships with distributors and medical supply companies. Key revenue streams include the initial sale of the AnaConDa device, ongoing sales of consumable products necessary for its operation, and potential licensing agreements for technology use. Additionally, Sedana Medical benefits from collaborations with healthcare institutions for clinical studies, which can also lead to increased product adoption and sales.

Sedana Medical AB Financial Statement Overview

Summary

Sedana Medical AB shows modest revenue growth but struggles with profitability, reflected in negative net profit and EBIT margins. The balance sheet is stable with low leverage, but cash flow challenges persist, impacting operational sustainability.

Income Statement

Sedana Medical AB shows a modest revenue growth rate of 4.64% in the TTM, indicating some positive momentum. However, the company is struggling with profitability, as evidenced by negative net profit margins (-25.93%) and EBIT margins (-20.65%). The gross profit margin remains strong at 70.37%, suggesting efficient cost management at the production level, but overall profitability is hindered by high operating expenses.

Balance Sheet

The company's balance sheet is relatively stable with a low debt-to-equity ratio of 0.0053, indicating minimal leverage and financial risk. However, the return on equity is negative (-5.40%), reflecting ongoing losses and challenges in generating returns for shareholders. The equity ratio is healthy, suggesting a strong capital structure.

Cash Flow

Cash flow analysis reveals significant challenges, with negative operating cash flow and a declining free cash flow growth rate (-15.01%). The free cash flow to net income ratio is high at 4.59, indicating that while the company is generating cash relative to its net losses, it is still insufficient to cover operational needs.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	196.12M	178.75M	153.87M	122.86M	159.15M	141.77M
Gross Profit	138.02M	126.14M	108.98M	86.07M	106.71M	88.90M
EBITDA	-18.92M	-4.03M	-51.67M	-64.87M	-49.10M	-17.22M
Net Income	-50.85M	-10.67M	-59.61M	-73.51M	-57.97M	-27.14M
Balance Sheet
Total Assets	978.89M	1.02B	1.01B	1.08B	1.17B	600.10M
Cash, Cash Equivalents and Short-Term Investments	130.71M	193.96M	381.80M	607.74M	836.18M	376.17M
Total Debt	4.87M	5.92M	4.31M	8.74M	8.87M	8.29M
Total Liabilities	58.66M	61.17M	44.06M	52.43M	66.12M	49.00M
Stockholders Equity	920.23M	958.23M	970.00M	1.03B	1.10B	551.09M
Cash Flow
Free Cash Flow	-130.77M	-186.77M	-206.95M	-253.22M	-151.48M	-92.47M
Operating Cash Flow	-28.48M	-11.77M	-38.06M	-115.43M	-41.22M	-7.85M
Investing Cash Flow	-127.15M	-44.67M	-321.96M	-137.78M	-110.25M	-84.62M
Financing Cash Flow	-3.91M	-3.57M	-4.86M	-1.51M	605.07M	5.79M

Sedana Medical AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 12.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SEDANA, the sentiment is Negative. The current price of 12.24 is below the 20-day moving average (MA) of 12.56, below the 50-day MA of 13.88, and below the 200-day MA of 13.63, indicating a bearish trend. The MACD of -0.27 indicates Negative momentum. The RSI at 41.44 is Neutral, neither overbought nor oversold. The STOCH value of 39.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SEDANA.

Sedana Medical AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	64 Neutral	€1.11B	43.19	7.87%	―	-10.34%	-59.69%
PAX	62 Neutral	$1.58B	142.11	2.64%	―	14.28%	-68.33%
OSSD	57 Neutral	kr1.44B	―	―	―	36.23%	63.14%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SEDANA	48 Neutral	€1.22B	―	-5.40%	―	16.27%	-22.61%
INTEG.B	43 Neutral	€175.58M	―	-18.35%	―	-5.63%	-1373.99%
SEZI	40 Neutral	$924.42M	―	-35.36%	―	71.41%	17.26%

Sedana Medical AB Corporate Events

Sedana Medical Reports Strong Q2 2025 Sales Growth Amid Currency Challenges

Sedana Medical AB reported a strong sales growth of 21% in Q2 2025, driven by increased sales and reduced operating costs, despite facing challenges from unrealized currency effects. The company continues its registration preparation work in the USA, impacting cash flow from investments in intangible assets, while maintaining a focus on improving cash flow from operations outside the US.

Sedana Medical’s Paediatric Study Published in The Lancet

Sedana Medical AB has announced the publication of its IsoCOMFORT paediatric study in The Lancet Respiratory Medicine, marking a significant achievement in paediatric critical care research. The study, which is the largest of its kind for inhaled isoflurane sedation, demonstrated the efficacy and safety of Sedaconda ACD in children aged 3-17, leading to paediatric approval in 13 European countries and extending market exclusivity until 2032. This development not only enhances Sedana Medical’s market position but also provides a significant clinical benefit over existing therapies, impacting stakeholders positively.

Sedana Medical to Present Q2 2025 Interim Report

Sedana Medical AB is set to release its interim report for the second quarter of 2025 on July 18, with a presentation scheduled for the same day. The report will be presented by the CEO, CFO, and CMO, providing insights into the company’s performance and strategy, which could impact its market positioning and stakeholder interests.

Sedana Medical’s US Studies Achieve Key Endpoint in Opioid Reduction

Sedana Medical AB announced that its pivotal US studies, INSPiRE-ICU 1 and 2, have successfully met a key secondary endpoint by demonstrating a significant reduction in opioid doses compared to the control group. This achievement supports the company’s aim for US registration of its Sedaconda ACD device and isoflurane for ICU sedation, potentially impacting the US market by providing an alternative to opioid use. The results, which align with previous European studies, will be crucial for the FDA’s assessment of Sedana Medical’s marketing authorization application.